Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
- Citation:
- Cancer Med vol 5 (9) 2249-2260
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- collection
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 6
- Parents:
- 2138
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Bristol Myers; Sanofi-Synthelabo
- Grants:
- U24CA196171, U10 CA180821, U10 CA180882, , U10 CA047577, U10 CA031946, U10 CA033601, U24 CA196171, U10 CA180867, U10 CA180838
- Corr. Author:
- Authors:
- Ace J. Hatch Alexander B. Sibley Mark D. Starr J. Chris Brady Chen Jiang Jingquan Jia Daniel L. Bowers Herbert Pang Kouros Owzar Donna Niedzwiecki Federico Innocenti Alan P. Venook Herbert I. Hurwitz Andrew B. Nixon
- Networks:
- CA136, LAPS-MA036, LAPS-NC007, LAPS-NC010, MD001
- Study
- CALGB-80203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Biomarker, cetuximab, colorectal cancer, plasma